Autoantigen‐Dexamethasone Conjugate‐Loaded Liposomes Halt Arthritis Development in Mice

Abstract

AbstractThere is no curative treatment for chronic auto‐inflammatory diseases including rheumatoid arthritis, and current treatments can induce off‐target side effects due to systemic immune suppression. This work has previously shown that dexamethasone‐pulsed tolerogenic dendritic cells loaded with the arthritis‐specific antigen human proteoglycan can suppress arthritis development in a proteoglycan‐induced arthritis mouse model. To circumvent ex vivo dendritic cell culture, and enhance antigen‐specific effects, drug delivery vehicles, such as liposomes, provide an interesting approach. Here, this work uses anionic 1,2‐distearoyl‐sn‐glycero‐3‐phosphoglycerol liposomes with enhanced loading of human proteoglycan‐dexamethasone conjugates by cationic lysine tetramer addition. Antigen‐pulsed tolerogenic dendritic cells induced by liposomal dexamethasone in vitro enhanced antigen‐specific regulatory T cells to a similar extent as dexamethasone‐induced tolerogenic dendritic cells. In an inflammatory adoptive transfer model, mice injected with antigen‐dexamethasone liposomes have significantly higher antigen‐specific type 1 regulatory T cells than mice injected with antigen only. The liposomes significantly inhibit the progression of arthritis compared to controls in preventative and therapeutic proteoglycan‐induced arthritis mouse models. This coincides with systemic tolerance induction and an increase in IL10 expression in the paws of mice. In conclusion, a single administration of autoantigen and dexamethasone‐loaded liposomes seems to be a promising antigen‐specific treatment strategy for arthritis in mice.